Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP07774640A	2017-03-08	Teva Pharmaceutical Industries Ltd	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178550	TERSERA	Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor	Apr, 2027 (3 years from now)
US7049320	TERSERA	NK1 antagonists	Aug, 2028 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299	TERSERA	NK1 antagonists	Dec, 2022 (9 months ago)
US8404702	TERSERA	Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Apr, 2027 (3 years from now)
US7563801	TERSERA	Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Apr, 2027 (3 years from now)
US7981905	TERSERA	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Apr, 2027 (3 years from now)
US8470842	TERSERA	Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor	Jan, 2029 (5 years from now)
US8361500	TERSERA	Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom	Oct, 2029 (6 years from now)
US9101615	TERSERA	Intravenous formulations of neurokinin-1 antagonists	Jul, 2032 (8 years from now)